MARKET

ATHA

ATHA

Athira Pharma, Inc.
NASDAQ
0.2800
+0.0100
+3.70%
After Hours: 0.2862 +0.0062 +2.21% 18:47 05/13 EDT
OPEN
0.2673
PREV CLOSE
0.2700
HIGH
0.2997
LOW
0.2580
VOLUME
1.10M
TURNOVER
--
52 WEEK HIGH
3.670
52 WEEK LOW
0.2195
MARKET CAP
10.93M
P/E (TTM)
-0.1111
1D
5D
1M
3M
1Y
5Y
1D
Athira Pharma to present data from first-in-human Phase 1 trial of ATH-1105
TipRanks · 7h ago
Athira Pharma To Present Data From Phase 1 Clinical Trial Of ATH-1105 In Healthy Volunteers At 4Th Annual ALS Drug Development Summit
Benzinga · 8h ago
Athira Pharma to Present Data from First-in-Human Phase 1 Clinical Trial of ATH-1105 at the 4th Annual ALS Drug Development Summit
Barchart · 13h ago
Weekly Report: what happened at ATHA last week (0505-0509)?
Weekly Report · 1d ago
Athira Pharma Reports Reduced Losses and Strategic Focus
TipRanks · 3d ago
Athira Pharma GAAP EPS of -$0.23 beats by $0.01
Seeking Alpha · 4d ago
Athira Pharma Q1 EPS $(0.23) Up From $(0.69) YoY
Benzinga · 4d ago
ATHIRA PHARMA REPORTS FIRST QUARTER 2025 FINANCIAL RESULTS AND PIPELINE AND BUSINESS UPDATES
Reuters · 4d ago
More
About ATHA
More
Athira Pharma, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing small molecules to restore neuronal health and slow neurodegeneration. Its approach is designed to modulate the neurotrophic hepatocyte growth factor (HGF) system, which is critical to normal brain function. The Company’s lead drug candidate is ATH-1105. ATH-1105 is a novel, orally available, brain-penetrant small-molecule drug candidate designed to positively modulate the neurotrophic HGF system for the potential treatment of neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS), Alzheimer’s disease (AD), and Parkinson’s disease (PD). ATH-1105 is in development for the potential treatment of ALS. Its ATH-1020 is a novel, orally available small molecule drug candidate designed to positively modulate the neurotrophic HGF system. It has evaluated several other compounds in preclinical discovery and development for neurodegenerative diseases and other indications.
Recently
Symbol
Price
%Change

Webull offers Athira Pharma Inc stock information, including NASDAQ: ATHA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ATHA stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ATHA stock methods without spending real money on the virtual paper trading platform.